A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris
- PMID: 8485067
- DOI: 10.1007/BF00878320
A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris
Abstract
The antianginal activities of nicorandil, 10 and 20 mg bid, and metoprolol, 100 mg bid, were compared in patients with stable effort angina pectoris in a randomized, double-blind parallel group study lasting 7 weeks. Twenty patients were enrolled into the trial and 16 patients completed the study. To evaluate the anti-ischemic effects of the two drugs, a treadmill exercise test was performed after a 1-week placebo run-in period and 6 weeks of treatment. On the same occasions, weekly sublingual nitroglycerin consumption and the number of anginal attacks were also recorded in the patient's diary. The total duration of exercise increased significantly with both nicorandil, 10 and 20 mg, and metoprolol (p < 0.01). Similar improvements were observed in the time to onset of ischemia with both treatments (p < 0.01). The double product at maximal comparable workload (MAX 1) was reduced with the two drugs (p < 0.05 for nicorandil and p < 0.01 for metoprolol), while at the maximal exercise time (MAX 2) it was reduced with metoprolol (p < 0.01) and slightly but not significantly increased with both doses of nicorandil. Weekly sublingual nitroglycerin consumption and anginal attacks were also significantly reduced a similar manner by both treatments (p < 0.01). In conclusion, nicorandil, 10 and 20 mg bid, exerted an anti-ischemic effect comparable with that of metoprolol in patients with stable effort angina pectoris.
Similar articles
-
Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study.J Cardiovasc Pharmacol. 1992;20 Suppl 3:S67-73. doi: 10.1097/00005344-199206203-00012. J Cardiovasc Pharmacol. 1992. PMID: 1282179 Clinical Trial.
-
A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina.Eur Heart J. 1993 Jul;14 Suppl B:35-9. doi: 10.1093/eurheartj/14.suppl_b.35. Eur Heart J. 1993. PMID: 8370371 Clinical Trial.
-
Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study.J Cardiovasc Pharmacol. 1992;20 Suppl 3:S59-66. J Cardiovasc Pharmacol. 1992. PMID: 1282178 Clinical Trial.
-
A potassium channel opener as monotherapy in chronic stable angina pectoris: comparison with placebo.Eur Heart J. 1993 Jul;14 Suppl B:25-9. doi: 10.1093/eurheartj/14.suppl_b.25. Eur Heart J. 1993. PMID: 8370369 Review.
-
Pharmacology and therapeutic effects of nicorandil.Cardiovasc Drugs Ther. 1990 Aug;4(4):1075-88. doi: 10.1007/BF01856503. Cardiovasc Drugs Ther. 1990. PMID: 2150592 Review.
Cited by
-
K(ATP) channel therapeutics at the bedside.J Mol Cell Cardiol. 2005 Jul;39(1):99-112. doi: 10.1016/j.yjmcc.2005.04.006. J Mol Cell Cardiol. 2005. PMID: 15953614 Free PMC article. Review.
-
Pharmacological treatment of chronic stable angina pectoris.Clin Med (Lond). 2013 Feb;13(1):63-70. doi: 10.7861/clinmedicine.13-1-63. Clin Med (Lond). 2013. PMID: 23472498 Free PMC article. Review.
-
Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients.Drugs. 2004;64(17):1941-55. doi: 10.2165/00003495-200464170-00012. Drugs. 2004. PMID: 15329045 Review.
-
Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention.Med Sci Monit. 2017 Jun 15;23:2924-2930. doi: 10.12659/msm.902324. Med Sci Monit. 2017. PMID: 28617765 Free PMC article. Clinical Trial.
-
Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.Drugs. 2000 Oct;60(4):955-74. doi: 10.2165/00003495-200060040-00007. Drugs. 2000. PMID: 11085202 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical